Pricing Log in Create free account

CRISPR Therapeutics AG (CRSP) vs PTC Therapeutics, Inc. (PTCT)

CRISPR Therapeutics AG and PTC Therapeutics, Inc. are both Biotechnology companies. CRISPR Therapeutics AG and PTC Therapeutics, Inc. are of similar size ($5.1B and $5.0B). PTC Therapeutics, Inc. grew revenue faster over the last twelve months: −42.8% against −64.8%. PTC Therapeutics, Inc. has the higher net margin (−3.80% vs −3,368.7%) and the higher return on invested capital (15.2% vs 0.00%). Across the 17 metrics below, PTC Therapeutics, Inc. leads on 14 and CRISPR Therapeutics AG on 3.

Valuation

Metric CRSP PTCT Biotechnology median
P/E n/m n/m 8.50
P/S 355.30 4.87 9.71
P/B 2.72 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 34.41 0.64
EV/Sales 222.52 5.55 9.21
Earnings yield (9.66%) (0.83%) (33.15%)
Free cash flow yield (7.80%) (6.11%) (25.50%)

Profitability

Metric CRSP PTCT Biotechnology median
Gross margin 100.00% 92.99% 65.16%
Operating margin (3,989.99%) 12.45% 0.00%
Net margin (3,368.72%) (3.80%) 0.00%
Free cash flow margin (2,772.74%) (29.76%) 0.00%
Return on equity (26.09%) 20.64% (56.36%)
Return on assets (19.28%) (1.30%) (48.04%)
Return on invested capital 0.00% 15.16% 0.00%

Growth

Metric CRSP PTCT Biotechnology median
Revenue growth (TTM) (64.80%) (42.84%) 6.02%
EPS growth (last fiscal year) (49.08%) 264.48% 30.26%
Revenue growth, 5-year CAGR 37.31% 35.37% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRSP PTCT Biotechnology median
Debt to equity 0.34 (17.61) 0.00
Current ratio 17.85 3.39 4.72
Net debt to EBITDA 3.06 0.73 0.96

Dividend

Metric CRSP PTCT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRSP PTCT Biotechnology median
Market cap 4.98b 5.09b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack